Combinations of immune-checkpoint blockade and radiotherapy to modulate antitumor immunity have mainly focused on manipulating T cells. A study now shows that combining radiotherapy with activation of macrophages yields potent, abscopal effects in mouse tumor models that may be ready for translation into early clinical trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McLaughlin, M. et al. Nat. Rev. Cancer 20, 203–217 (2020).
Nishiga, Y. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00456-0 (2022).
Willingham, S. B. et al. Proc. Natl Acad. Sci. USA 109, 6662–6627 (2012).
Weiskopf, K. et al. J. Clin. Invest. 126, 2610–2620 (2016).
Chan, J. M. et al. Cancer Cell 39, 1479–1496.e18 (2021).
Maute, R., Xu, J. & Weissman, I. L. 13, 100070 (2022).
Slotman, B. et al. N. Engl. J. Med. 357, 664–672 (2007).
Slotman, B. J. et al. Lancet 385, 36–42 (2015).
Shi, X. & Shiao, S. L. Transl. Res. 191, 64–80 (2018).
Rodriguez-Ruiz, M. E. et al. Cancer Res. 76, 5994–6005 (2016).
Mestas, J. & Hughes, C. C. W. J. Immunol. 172, 2731–2738 (2004).
Reck, M. et al. Ann. Oncol. 24, 75–83 (2013).
Golden, E. B. et al. Lancet Oncol. 16, 795–803 (2015).
Lee, N. Y. et al. Lancet Oncol. 22, 450–462 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.A.B. has received consulting fees from Regeneron and leads contracted research supported by Regeneron, Alpha Tau Medical, Merck, Amgen, Elekta and EMD Serono.
Rights and permissions
About this article
Cite this article
Barker, C.A., Riaz, N. A macrophage-activated abscopal effect. Nat Cancer 3, 1282–1283 (2022). https://doi.org/10.1038/s43018-022-00464-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-022-00464-0